EPIC Program Annual Data Tables 2008-2009 Appendix: Table VIII
Rank by Number of Claims | Drug and Strength | Drug Type** | Number of Claims | EPIC Payments | Rank by Payment |
---|---|---|---|---|---|
Top 20 Totals | 2,066,244 | $60,312,123 | |||
Percent of Top 20 Drugs to Total Paid Claims | 20.40% | 15.88% | |||
1 | PLAVIX (75 MG) | SS | 184,753 | $17,234,750 | 1 |
2 | HYDROCHLOROTHIAZIDE (25 MG) | Gen | 173,312 | $144,237 | 438 |
3 | OMEPRAZOLE (20 MG) | Gen | 135,790 | $1,526,423 | 43 |
4 | FUROSEMIDE (40 MG) | Gen | 130,240 | $190,832 | 349 |
5 | AMLODIPINE BESYLATE (5 MG) | Gen | 113,503 | $346,046 | 213 |
6 | NEXIUM (40 MG) | SS | 109,156 | $12,726,312 | 2 |
7 | ALENDRONATE SODIUM (70 MG) | Gen | 104,608 | $596,037 | 123 |
8 | LIPITOR (10 MG) | SS | 103,607 | $6,245,068 | 5 |
9 | SIMVASTATIN (20 MG) | Gen | 99,577 | $391,750 | 190 |
10 | FUROSEMIDE (20 MG) | Gen | 98,122 | $118,356 | 508 |
11 | AMLODIPINE BESYLATE (10 MG) | Gen | 91,162 | $289,148 | 246 |
12 | METOPROLOL TARTRATE (50 MG) | Gen | 90,959 | $156,683 | 411 |
13 | SIMVASTATIN (40 MG) | Gen | 89,396 | $398,479 | 185 |
14 | LIPITOR (20 MG) | SS | 85,484 | $7,326,087 | 4 |
15 | SPIRIVA (18MCG) | SS | 79,470 | $5,929,431 | 7 |
16 | METFORMIN HCL (500 MG) | Gen | 79,375 | $240,972 | 288 |
17 | METOPROLOL TARTRATE (25 MG) | Gen | 76,311 | $141,290 | 446 |
18 | VITAMIN D (50000 UNIT) | Gen | 73,953 | $516,142 | 145 |
19 | FLOMAX (0.4 MG) | SS | 73,896 | $4,888,175 | 8 |
20 | METOPROLOL SUCCINATE (50 MG) | Gen | 73,570 | $905,905 | 85 |
* Table VIII lists the top 20 drugs ranked by number of adjudicated claims for the program year (October 1, 2008-September 30, 2009) as well as the percentage of the totals they represent for the year.
** Drug Type values are BNMS='Brand Name Multi-Source', Gen='Generic and SS='Sole Source.'